Apixaban clinical trials
Apixaban is named as an intervention in 41 current clinical trials in our Canada, Denmark, France, South Korea, USA, China, Israel, Sweden, Norway, Germany, Poland, Japan, Italy, Brazil, Australia, Switzerland, India, Spain, Netherlands, Mexico, UK, Belgium, Czechia, Portugal, Turkey, Taiwan, Singapore and Egypt registers. 28 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Regeneron Pharmaceuticals (4). The most-studied condition is Atrial Fibrillation. The EU clinical trials register (CTIS) separately lists 4 authorised or ongoing trials.
Where Apixaban is approved
All regulators →Of the three regulators tracked here, the first to approve Apixaban was the EU, on 18 May 2011. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Apixaban patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Apixaban, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 3 listed patents; the last listed expires 22 May 2041 (US 11896586, including a 6-month paediatric extension).
- Latest patent on the drug substance itself: 21 May 2027 (US 6967208, with paediatric extension).
- Exclusivity PED: Pediatric exclusivity, until 17 Oct 2028.
- Exclusivity NPP: New patient population, until 17 Apr 2028.
- Exclusivity NS: New strength, until 17 Apr 2028.
- Exclusivity NP: New product, until 17 Apr 2028.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Apixaban
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Apixaban works
All drug targets →- Coagulation factor X inhibitor InhibitorTarget: F10 coagulation factor X✓ In ChEMBL and the Guide to Pharmacology
- COVID-19Phase 3
- ThrombocytopeniaPhase 3
- ThromboembolismPhase 3
- Aortic stenosisPhase 3
- Heart valve disorderPhase 3
- HemorrhagePhase 3
- IschemiaPhase 3
- Myocardial infarctionPhase 3
- Transient ischemic attackPhase 3
- Venous malformationPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL231779, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6390, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Apixaban
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 3 technology appraisals of Apixaban. 3 are current, and 3 of these recommend it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism NICE TA341 | Recommended | 4 Jun 2015 | Current |
| Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation NICE TA275 | Recommended | 27 Feb 2013 Updated 2 Jul 2021 | Current |
| Apixaban for preventing venous thromboembolism after hip or knee replacement surgery NICE TA245 | Recommended | 25 Jan 2012 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Apixaban
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 36 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: Eliquis, Apixaban Accord (generic)EMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Apixaban
- ATC code
- B01AF02
- ChEMBL
- CHEMBL231779
- DrugBank
- DB06605
- PubChem CID
- 10182969
- CAS number
- 503612-47-3
- FDA UNII
- 3Z9Y7UWC1J
- Wikidata
- Q414462
- Wikipedia
- Apixaban
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Apixaban
41 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Apixaban in the EU trials register (CTIS)
4 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Apixaban. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Apixaban across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
36 single-substance products containing Apixaban on the HPRA medicines list.
- Apixaban Abdi 5 mg film-coated tabletAbdi Farma GmbH · PA23405/002/002
- Apixaban Accord 2.5 mg film-coated tabletsAccord Healthcare S.L.U. · EU/1/20/1458/001-020
- Apixaban Accord 5 mg film-coated tabletsAccord Healthcare S.L.U. · EU/1/20/1458/021-046
- Eliquis 0.15 mg granules in capsules for openingBristol-Myers Squibb/Pfizer EEIG · EU/1/11/691/016
- Eliquis 0.5 mg coated granule in sachetBristol-Myers Squibb/Pfizer EEIG · EU/1/11/691/017
Supply shortages
No entry for Apixaban in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Apixaban
64 conditionsAll 64 conditions
| Condition (as registered) | Trials |
|---|---|
| Atrial Fibrillation | 9 |
| Atrial Fibrillation (AF) | 4 |
| Stroke | 4 |
| Venous Thromboembolism (VTE) | 3 |
| Cirrhosis | 3 |
| Portal Vein Thrombosis | 3 |
| Intracerebral Hemorrhage | 3 |
| Venous Thromboembolism | 3 |
| Splenectomy | 2 |
| Hypertension, Portal | 2 |
| Pulmonary Embolism | 2 |
| Deep Vein Thrombosis | 2 |
| Liver Cirrhosis | 2 |
| Ischemia Stroke | 1 |
| Bleeding Post Cardiac Surgery | 1 |
| Indication for Anticoagulation | 1 |
| Microhaemorrhage | 1 |
| Antiphospholipid Syndrome | 1 |
| Thrombosis | 1 |
| Anticoagulants Causing Adverse Effects in Therapeutic Use | 1 |
| Multiple Myeloma | 1 |
| Total Knee Replacement | 1 |
| Intrahepatic Non Cirrhotic Portal Hypertension | 1 |
| Ischemic Stroke | 1 |
| Cerebral Infarction | 1 |
| Aortic Valve Disease | 1 |
| Hip Fracture Surgery | 1 |
| Cardiovascular Prevention | 1 |
| Left Ventricular Thrombus | 1 |
| Acute Myocardial Infarction | 1 |
| Takotsubo Syndrome | 1 |
| Non-valvular Atrial Fibrillation (AF) | 1 |
| Aortic Valve Stenosis | 1 |
| Cardiovascular Diseases | 1 |
| Heart Diseases | 1 |
| Heart Valve Diseases | 1 |
| Atrial Flutter | 1 |
| Lymphoma | 1 |
| Leukemia | 1 |
| Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma | 1 |
| Venous Thromboembolic Disease | 1 |
| Venous Malformation, Low Flow | 1 |
| Anticoagulants | 1 |
| Obesity, Morbid | 1 |
| Staphylococcus Aureus Endocarditis | 1 |
| Staphylococcus Aureus Septicemia | 1 |
| Staphylococcus Aureus Bacteremia | 1 |
| Staphylococcus Aureus Bloodstream Infection | 1 |
| Cancer | 1 |
| Upper Extremity Deep Vein Thrombosis | 1 |
| Catheter-Related Infections | 1 |
| Hemodialysis Access Failure | 1 |
| Kidney Disease, End-Stage | 1 |
| Hemodialysis Catheter | 1 |
| Active Cancer | 1 |
| Coronary Arterial Disease (CAD) | 1 |
| Ischemic | 1 |
| Intracrnaial Arterioscelrosis | 1 |
| Spinal Cord Injuries | 1 |
| Spinal Diseases | 1 |
| Pulmonary Embolism and Thrombosis | 1 |
| Thrombocytopenia | 1 |
| Recurrent Venous Thromboembolism | 1 |
| HCC - Hepatocellular Carcinoma | 1 |
Sponsors
lead sponsor per trial+ 16 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Apixaban trials
How many clinical trials are testing Apixaban?
41 current trials in our Canada, Denmark, France, South Korea, USA, China, Israel, Sweden, Norway, Germany, Poland, Japan, Italy, Brazil, Australia, Switzerland, India, Spain, Netherlands, Mexico, UK, Belgium, Czechia, Portugal, Turkey, Taiwan, Singapore and Egypt registers name Apixaban (also registered as SUB25425) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Apixaban trials recruiting patients?
Yes. 28 of the 41 trials are recruiting: 7 with sites in Canada, 3 with sites in Denmark, 4 with sites in France, 4 with sites in South Korea, 4 with sites in USA, 2 with sites in China, 4 with sites in Israel, 4 with sites in Sweden, 3 with sites in Norway, 3 with sites in Germany, 2 with sites in Poland, 3 with sites in Japan, 1 with sites in Italy, 2 with sites in Brazil, 2 with sites in Australia, 3 with sites in Switzerland, 1 with sites in India, 1 with sites in Spain, 1 with sites in Netherlands, 1 with sites in Mexico and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Apixaban clinical trials?
Regeneron Pharmaceuticals (4), Assistance Publique - Hôpitaux de Paris (3), Population Health Research Institute (2) and Northern Jiangsu People's Hospital (2), among 31 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Apixaban licensed in Ireland?
Yes. The HPRA medicines list includes 36 single-substance products containing Apixaban, for example Apixaban Abdi 5 mg film-coated tablet (Abdi Farma GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Apixaban shortage?
Not in the lists we track: Apixaban has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Apixaban works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Apixaban works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Apixaban (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.